KYORIN Pharmaceutical Co Ltd (Kyorin), formerly KYORIN Holdings Inc, manufactures and sells prescription medicine, quasi-drugs and diagnostic drugs. The company leverages its strong R&D capabilities, improved operational performance, and business performance in generic drug business could strengthen its position, even as business concentration is major area of concern for the company. Going forward, stringent government regulations, intense competition and uncertain R&D outcomes could affect its business operations. However, launch of new products, pipeline products, and increasing healthcare expenditure could provide ample growth opportunities to the company.
Strengths
- Focus on Research and Development
- Proin vel
- Proin vel
- Proin vel
Weaknesses
- Business Concentration
- Proin vel
- Proin vel
- Proin vel
Opportunities
- Pipeline Products
- Proin vel
- Proin vel
- Proin vel
Threats
- Intense Competition
- Proin vel
- Proin vel
- Proin vel
Strengths
Weaknesses
Opportunities
Threats
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer